• Professor, Global Health
  • Professor, Medicine - Allergy and Infectious Dis.
  • Professor, Epidemiology
Scott McClelland

325 9th Avenue
Box 359909
Seattle, WA 98104
United States

Phone Number: 
Select from the following:

Dr. McClelland is an Infectious Disease specialist. His research focuses on women's reproductive health, STIs, and HIV in Kenya. Dr. McClelland is co-PI of the University of Washington Vaccine and Treatment Evaluation Unit and site PI for the AstraZeneca COVID-19 vaccine trial.

  • BS (University of Washington)
  • MD (University of Washington)
  • MPH (University of Washington)
Country Affiliations 
  • Kiswahili
  • Spanish
Health Topics 
  • COVID-19
  • STDs (other than HIV)

McClelland RS, Sangaré L, Hassan WM, Lavreys, L, Mandaliya K, Kiarie J, Ndinya-Achola J, Jaoko W, Baeten JM. Infection with Trichomonas vaginalis increases the risk for HIV-1 acquisition. J Infect Dis 2007; 195:698-702.

McClelland RS†, Lingappa JR†, Srinivasan S, Kinuthia J, John-Stewart GC, Jaoko W, Richardson BA , Yuhas K, Fiedler TL, Mandaliya KN, Munch MM, Mugo NR, Cohen CR, Baeten JM, Celum C, Overbaugh J, Fredricks DN. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis 2018; 18:554-64.

Odeny TA, Hughes JP, Bukusi EA, Akama E, Geng EH, Holmes KK, McClelland RS. Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya. PLoS Med. 2019;16:e1002924.